A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

NCT06830720 · clinicaltrials.gov ↗

RECRUITING

Status

3250

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: ribociclib + AI ± LHRH
DRUG: abemaciclib + ET ± LHRH
DRUG: ET mono ± LHRH

Sponsor

Novartis Pharmaceuticals